BioVie Inc. (BIVI) Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites Transcript
BioVie Inc. provided updates on its clinical trials for Bezisterim and BIV201, targeting conditions such as Parkinson's and Alzheimer's. The discussion included insights from the company's President and CEO, Cuong Do, during a conference call. The event was accessible through various social media platforms.
- ▪BioVie Inc. is focused on developing treatments for Parkinson's, Alzheimer's, and ascites.
- ▪The company's clinical updates were presented by Cuong Do, the President and CEO.
- ▪The conference call was broadcasted on multiple social media platforms.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4911226-biovie-inc-bivi-discusses-clinical-updates-on-bezisterim-and-biv201-for-parkinsons-alzheimers"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
